Yu D, Vydiswaran V
JMIR Med Inform. 2022; 10(9):e38140.
PMID: 36170004
PMC: 9557755.
DOI: 10.2196/38140.
Jagannatha A, Liu F, Liu W, Yu H
Drug Saf. 2019; 42(1):99-111.
PMID: 30649735
PMC: 6860017.
DOI: 10.1007/s40264-018-0762-z.
Munkhdalai T, Liu F, Yu H
JMIR Public Health Surveill. 2018; 4(2):e29.
PMID: 29695376
PMC: 5943628.
DOI: 10.2196/publichealth.9361.
Hadi M, Neoh C, Zin R, Elrggal M, Cheema E
Integr Pharm Res Pract. 2018; 6:91-98.
PMID: 29354555
PMC: 5774327.
DOI: 10.2147/IPRP.S105881.
Alshammari T, Al-Kathiri W, Le Louet H, Aljadhey H
Saudi Med J. 2015; 36(7):821-8.
PMID: 26108586
PMC: 4503901.
DOI: 10.15537/smj.2015.7.11751.
Comparison of the safety of seven iodinated contrast media.
Seong J, Choi N, Lee J, Chang Y, Kim Y, Yang B
J Korean Med Sci. 2013; 28(12):1703-10.
PMID: 24339697
PMC: 3857363.
DOI: 10.3346/jkms.2013.28.12.1703.
Spontaneous reporting of adverse drug reactions through electronic submission from regional society healthcare professionals in Korea.
Lee J, Park K, Moon H, Lee Y, Park J, Hong C
Yonsei Med J. 2012; 53(5):1022-7.
PMID: 22869488
PMC: 3423839.
DOI: 10.3349/ymj.2012.53.5.1022.
Is there still a role for spontaneous reporting of adverse drug reactions?.
Lexchin J
CMAJ. 2006; 174(2):191-2.
PMID: 16415466
PMC: 1329459.
DOI: 10.1503/cmaj.050971.
Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
Thiessard F, Roux E, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Tubert-Bitter P
Drug Saf. 2005; 28(8):731-40.
PMID: 16048358
DOI: 10.2165/00002018-200528080-00007.
Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions.
van Puijenbroek E, Diemont W, van Grootheest K
Drug Saf. 2003; 26(5):293-301.
PMID: 12650632
DOI: 10.2165/00002018-200326050-00001.
Antibiotics, the pill, and pregnancy.
Mastrantonio M, Minhas H, Gammon A
J Accid Emerg Med. 1999; 16(4):268-70.
PMID: 10417934
PMC: 1343367.
DOI: 10.1136/emj.16.4.268.
Cost-effective prescribing in elderly people.
Morgan D, Sutters C, Livesley B
Pharmacoeconomics. 1992; 1(6):387-93.
PMID: 10147020
DOI: 10.2165/00019053-199201060-00001.
Marketing aspects of company-sponsored postmarketing surveillance studies.
Stephens M
Drug Saf. 1993; 8(1):1-8.
PMID: 8471183
DOI: 10.2165/00002018-199308010-00001.
False-positives in spontaneous reporting: should we worry about them?.
Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F
Br J Clin Pharmacol. 1994; 38(5):401-4.
PMID: 7893579
PMC: 1364871.
DOI: 10.1111/j.1365-2125.1994.tb04373.x.
Adverse Drug Reaction Reporting Program of the Ontario Medical Association: the first 3 years.
Gowdey C, Brennan M
Can Med Assoc J. 1985; 132(1):19-23.
PMID: 3871167
PMC: 1346498.
Postmarketing surveillance of adverse drug reactions: problems and solutions.
Lortie F
CMAJ. 1986; 135(1):27-32.
PMID: 3719483
PMC: 1491132.
Techniques of postmarketing surveillance. An overview.
Carson J, Strom B
Med Toxicol. 1986; 1(4):237-46.
PMID: 3537618
DOI: 10.1007/BF03259840.
Improving adverse drug reaction monitoring.
McEwen J
Med Toxicol Adverse Drug Exp. 1987; 2(6):398-404.
PMID: 3431426
DOI: 10.1007/BF03259874.
Involving the patient in reporting adverse drug reactions.
Campbell J, HOWIE J
J R Coll Gen Pract. 1988; 38(313):370-1.
PMID: 3256650
PMC: 1711514.
New approaches to postmarketing surveillance.
Fisher S, BRYANT S, Kluge R
Psychopharmacology (Berl). 1986; 90(3):347-50.
PMID: 3097723
DOI: 10.1007/BF00179189.
